Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria

The original designation of “Arrhythmogenic right ventricular (dysplasia/) cardiomyopathy”(ARVC) was used by the scientists who first discovered the disease, in the pre-genetic and pre-cardiac magnetic resonance era, to describe a new heart muscle disease predominantly affecting the right ventricle,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2020-11, Vol.319, p.106-114
Hauptverfasser: Corrado, Domenico, Perazzolo Marra, Martina, Zorzi, Alessandro, Beffagna, Giorgia, Cipriani, Alberto, Lazzari, Manuel De, Migliore, Federico, Pilichou, Kalliopi, Rampazzo, Alessandra, Rigato, Ilaria, Rizzo, Stefania, Thiene, Gaetano, Anastasakis, Aris, Asimaki, Angeliki, Bucciarelli-Ducci, Chiara, Haugaa, Kristine H., Marchlinski, Francis E., Mazzanti, Andrea, McKenna, William J., Pantazis, Antonis, Pelliccia, Antonio, Schmied, Christian, Sharma, Sanjay, Wichter, Thomas, Bauce, Barbara, Basso, Cristina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The original designation of “Arrhythmogenic right ventricular (dysplasia/) cardiomyopathy”(ARVC) was used by the scientists who first discovered the disease, in the pre-genetic and pre-cardiac magnetic resonance era, to describe a new heart muscle disease predominantly affecting the right ventricle, whose cardinal clinical manifestation was the occurrence of malignant ventricular arrhythmias. Subsequently, autopsy investigations, genotype-phenotype correlations studies and the increasing use of contrast-enhancement cardiac magnetic resonance showed that the fibro-fatty replacement of the myocardium represents the distinctive phenotypic feature of the disease that affects the myocardium of both ventricles, with left ventricular involvement which may parallel or exceed the severity of right ventricular involvement. This has led to the new designation of “Arrhythmogenic Cardiomyopathy” (ACM), that represents the evolution of the original term of ARVC. The present International Expert Consensus document proposes an upgrade of the criteria for diagnosis of the entire spectrum of the phenotypic variants of ACM. The proposed “Padua criteria” derive from the diagnostic approach to ACM, which has been developed over 30 years by the multidisciplinary team of basic researchers and clinical cardiologists of the Medical School of the University of Padua. The Padua criteria are a working framework to improve the diagnosis of ACM by introducing new diagnostic criteria regarding tissue characterization findings by contrast-enhanced cardiac magnetic resonance, depolarization/repolarization ECG abnormalities and ventricular arrhythmia features for diagnosis of the left ventricular phenotype. The proposed diagnostic criteria need to be further validated by future clinical studies in large cohorts of patients. •Fibro-fatty myocardial replacement is the distinctive phenotypic feature of Arrhythmogenic cardiomyopathy (ACM);•ACM can affect both the right and left ventricle;•The 2010 International Task Force diagnostic criteria lacked specific criteria for diagnosis of left-sided variants of ACM;•The proposed Padua diagnostic criteria encompass dominant-right, biventricular and dominant-left ACM.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2020.06.005